Drugs / Convalescent Plasma
Convalescent Plasma
Trials 98 · started per year
today
1
1
1
80
5
2
2015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT04516954 | Aug 2020 → Mar 2021 | COVID-19 | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 0 | NCT04458363 | Jul → Sep 2020 | COVID-19 | Emory University | Completed | No outcome recorded |
| Phase 0 | NCT04353206 | Jun → Nov 2020 | COVID-19 | Noah Merin | Terminated | No outcome recorded |
| Phase 0 | NCT04565197 | May → Dec 2020 | COVID-19 | Lahore General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04355897 | Apr → Jul 2020 | COVID-19 | The Christ Hospital | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT04521036 | Dec 2020 → Jun 2021 | COVID-19 | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 1 | NCT04397757 | May 2020 → Feb 2021 | COVID-19 | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT04333355 | May → Aug 2020 | COVID-19 | TecSalud Investigación Clínica | Terminated | No outcome recorded |
| Phase 1 | NCT04407208 | May → Jun 2020 | COVID-19 | Biofarma | Completed | No outcome recorded |
| Phase 1 | NCT04388527 | Apr 2020 → Jan 2021 | COVID-19 | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT04869072 | Apr → Nov 2020 | COVID-19 | University of Zurich | Completed | No outcome recorded |
| Phase 1 | NCT04411602 | Apr 2020 → Apr 2021 | COVID-19, severe acute respiratory syndrome | Henry Ford Health System | Withdrawn | No outcome recorded |
| Phase 1 | NCT04554992 | Mar 2020 → Dec 2023 | COVID-19 | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04452812 | Jul 2020 → Mar 2021 | pneumonia | Universidad Autonoma de Coahuila | Unknown | No outcome recorded |
| Phase 1/2 | NCT04438694 | Jun 2020 → May 2021 | COVID-19 | Cairo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04356482 | May → Nov 2020 | COVID-19 | Institute for Social Security and Services for State Workers | Unknown | No outcome recorded |
| Phase 242 trials | ||||||
| Phase 2 | NCT05077930 | Jan → Apr 2022 | COVID-19, pneumonia | Tânia Portella Costa | Completed | No outcome recorded |
| Phase 2 | NCT05184127 | Apr → Sep 2021 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
| Phase 2 | NCT04390503 | Mar 2021 → Jan 2022 | COVID-19 | Andrew Eisenberger | Terminated | No outcome recorded |
| Phase 2 | NCT04730401 | Jan 2021 → Jan 2022 | COVID-19 | Helsinki University Central Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04712344 | Jan → Sep 2021 | COVID-19 | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 2 | NCT04681430 | Jan → Oct 2021 | COVID-19 | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 2 | NCT04528368 | Dec 2020 → Dec 2021 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 2 | NCT04456413 | Nov 2020 → Apr 2021 | COVID-19 | Hackensack Meridian Health | Terminated | No outcome recorded |
| Phase 2 | NCT04377568 | Oct 2020 → Dec 2021 | COVID-19 | The Hospital for Sick Children | Withdrawn | No outcome recorded |
| Phase 2 | NCT04467151 | Oct 2020 → Oct 2021 | COVID-19 | Kashif Khan | Withdrawn | No outcome recorded |
| Phase 2 | NCT04497324 | Sep 2020 → Apr 2021 | COVID-19 | Universidad Peruana Cayetano Heredia | Completed | No outcome recorded |
| Phase 2 | NCT04558476 | Sep 2020 → Apr 2022 | COVID-19, acute respiratory failure, severe acute respiratory syndrome | University of Liege | Completed | No outcome recorded |
| Phase 2 | NCT04524507 | Aug 2020 → Jan 2021 | COVID-19 | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT04513158 | Aug 2020 → Apr 2021 | COVID-19 | Joseph M. Flynn, D.O., MPH | Terminated | No outcome recorded |
| Phase 2 | NCT04480632 | Aug 2020 → Aug 2021 | COVID-19 | Fundación Cardiovascular de Colombia | Unknown | No outcome recorded |
| Phase 2 | NCT04432272 | Jul → Nov 2020 | COVID-19, severe acute respiratory syndrome | Corewell Health East | Terminated | No outcome recorded |
| Phase 2 | NCT04408040 | Jul 2020 → Sep 2021 | COVID-19 | Northside Hospital, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04468009 | Jun 2020 → Jan 2021 | COVID-19 | Hospital de Infecciosas Francisco Javier Muniz | Completed | No outcome recorded |
| Phase 2 | NCT04542967 | Jun → Sep 2020 | COVID-19 | Hospital Central Militar | Completed | No outcome recorded |
| Phase 2 | NCT04323800 | Jun 2020 → Apr 2021 | Coronaviridae infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT04421404 | Jun 2020 → Apr 2021 | COVID-19 | Priscilla Hsue, MD | Completed | No outcome recorded |
| Phase 2 | NCT04403477 | May → Jul 2020 | COVID-19 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT04569188 | May → Aug 2020 | COVID-19 | Azienda Socio Sanitaria Territoriale di Mantova | Completed | No outcome recorded |
| Phase 2 | NCT04374487 | May 2020 → Aug 2021 | COVID-19 | Max Healthcare Insititute Limited | Unknown | No outcome recorded |
| Phase 2 | NCT04442191 | May 2020 → May 2021 overdue | COVID-19 | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT04392232 | May 2020 → Sep 2021 | COVID-19 | TriHealth Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04385199 | May → Aug 2020 | COVID-19 | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2 | NCT04375098 | May → Aug 2020 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 2 | NCT04429854 | May 2020 → Apr 2021 | COVID-19 | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT04393727 | May → Sep 2020 | COVID-19 | Azienda Ospedaliero, Universitaria Pisana | Terminated | No outcome recorded |
| Phase 2 | NCT04434131 | Apr → Jul 2020 | COVID-19 | University of New Mexico | Completed | No outcome recorded |
| Phase 2 | NCT04359810 | Apr → Dec 2020 | COVID-19 | Max O'Donnell | Completed | No outcome recorded |
| Phase 2 | NCT04346446 | Apr → May 2020 | COVID-19 | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| Phase 2 | NCT04389710 | Apr → Nov 2020 | COVID-19 | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT04345991 | Apr 2020 → May 2021 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT04357106 | Apr → Jul 2020 | COVID-19 | Centro de Hematología y Medicina Interna | Unknown | No outcome recorded |
| Phase 2 | NCT04343261 | Apr → Jul 2020 | COVID-19 | Trinity Health Of New England | Completed | No outcome recorded |
| Phase 2 | NCT04343755 | Apr 2020 → Apr 2023 | COVID-19 | Hackensack Meridian Health | Terminated | No outcome recorded |
| Phase 2 | NCT04325672 | Apr 2020 → Dec 2022 | Coronaviridae infectious disease | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 2 | NCT05578391 | Jan → Dec 2020 | COVID-19 | Fundacin Biomedica Galicia Sur | Completed | No outcome recorded |
| Phase 2 | NCT04109144 | Nov 2019 → Jul 2023 | cirrhosis of liver | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02190799 | May 2014 → May 2016 | newborn respiratory distress syndrome | King Abdullah International Medical Research Center | Withdrawn | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT04873414 | Dec 2020 → Oct 2021 | COVID-19 | National Institute of Health Research and Development, Ministry of Health Republic of Indonesia | Unknown | No outcome recorded |
| Phase 2/3 | NCT04395170 | Sep → Dec 2020 | COVID-19 | Lifefactors Zona Franca, SAS | Unknown | No outcome recorded |
| Phase 2/3 | NCT04388410 | Aug → Nov 2020 | COVID-19 | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | No outcome recorded |
| Phase 2/3 | NCT04747158 | Aug → Dec 2020 | COVID-19 | Universidad Nacional de Asunción | Completed | No outcome recorded |
| Phase 2/3 | NCT04502472 | Jun → Sep 2020 | COVID-19 | Inova Health Care Services | Terminated | No outcome recorded |
| Phase 2/3 | NCT04374526 | May 2020 → May 2021 | COVID-19 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
| Phase 2/3 | NCT04380935 | May → Oct 2020 | COVID-19, adult acute respiratory distress syndrome | Indonesia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04342182 | Apr → Jul 2020 | COVID-19 | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT05271929 | Apr 2022 → Jan 2024 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Terminated | No outcome recorded |
| Phase 3 | NCT04539275 | Nov 2020 → Jun 2021 | COVID-19 | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 3 | NCT04589949 | Oct 2020 → Oct 2021 | COVID-19 | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT04516811 | Sep 2020 → Dec 2021 | COVID-19 | South African National Blood Service | Terminated | No outcome recorded |
| Phase 3 | NCT04372979 | Sep 2020 → Jun 2021 | COVID-19 | Central Directorate of the Army Health Service | Terminated | No outcome recorded |
| Phase 3 | NCT04355767 | Aug 2020 → Mar 2021 | COVID-19 | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT04547660 | Jul 2020 → Jan 2021 | COVID-19 | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT04425915 | Jun → Dec 2020 | COVID-19 | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| Phase 3 | NCT04391101 | Jun 2020 → Jun 2021 | COVID-19 | Hospital San Vicente Fundación | Unknown | No outcome recorded |
| Phase 3 | NCT06084351 | May → Oct 2020 | COVID-19 | Larkin Community Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT04362176 | Apr 2020 → Jul 2021 | COVID-19 | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04816942 | Apr → Jul 2020 | COVID-19, immunodeficiency disease | Ministry of Health and Population, Egypt | Completed | No outcome recorded |
| Phase 3 | NCT04376034 | Apr 2020 → Feb 2021 | COVID-19 | West Virginia University | Completed | No outcome recorded |
| Phase 3 | NCT05247307 | Mar 2020 → Dec 2021 | COVID-19 | Hospital Galdakao-Usansolo | Terminated | No outcome recorded |
| Phase 3 | NCT04348656 | Mar 2020 → Mar 2021 | COVID-19 | Hamilton Health Sciences Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT04642014 | Dec 2020 → Jan 2022 | — | Wroclaw Medical University | Terminated | No outcome recorded |
| — | NCT04716556 | Jul 2020 → Jan 2021 | COVID-19, viral pneumonia | Italian National Institute of Health | Completed | No outcome recorded |
| — | NCT04479163 | Jun → Oct 2020 | COVID-19 | Fundacion Infant | Completed | No outcome recorded |
| — | NCT04476888 | Apr → Sep 2020 | COVID-19 | Aga Khan University | Completed | No outcome recorded |
| — | NCT04600440 | Apr 2020 → Dec 2021 | COVID-19, respiratory failure | Skane University Hospital | Unknown | No outcome recorded |
| — | NCT04441424 | Apr → Jun 2020 | — | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| — | NCT04492501 | Apr → Jul 2020 | COVID-19, acute respiratory distress syndrome, cytokine release syndrome | UNICEF | Completed | No outcome recorded |
| — | NCT04327349 | Mar → May 2020 | Coronaviridae infectious disease | Mazandaran University of Medical Sciences | Unknown | No outcome recorded |
| Phase not stated8 trials | ||||||
| — | NCT04445207 | — | COVID-19 | Jonathan Gerber | No longer available | No outcome recorded |
| — | NCT04358211 | — | COVID-19 | Nakhle Saba, MD | No longer available | No outcome recorded |
| — | NCT04420988 | — | COVID-19 | Rutgers, The State University of New Jersey | No longer available | No outcome recorded |
| — | NCT04338360 | — | COVID-19 | Mayo Clinic | Approved for marketing | No outcome recorded |
| — | NCT04472572 | — | COVID-19 | Hackensack Meridian Health | No longer available | No outcome recorded |
| — | NCT05157165 | — | COVID-19 | Azienda Socio Sanitaria Territoriale di Mantova | No longer available | No outcome recorded |
| — | NCT04363034 | — | COVID-19 | University of Arkansas | No longer available | No outcome recorded |
| — | NCT04372368 | — | COVID-19 | University of Colorado, Denver | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04344535 Comparator | Apr 2020 → Jan 2021 | COVID-19 | Stony Brook University | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04415086 Comparator | Jun 2020 → Feb 2022 | COVID-19 | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04364737 Comparator | Apr 2020 → Mar 2021 | COVID-19 | NYU Langone Health | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04345289 Comparator | May 2020 → Mar 2021 | COVID-19, viral pneumonia | Thomas Benfield | Terminated | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02557672 Comparator | Aug 2016 → Jun 2021 | hemorrhagic disease | Mayo Clinic | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01306773 Comparator | Dec 2009 → Dec 2010 | influenza | The University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 111 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | convalescent plasma | “Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to...” PMID 33523609 ↗ Jan 202179“standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.” NCT05184127 ↗ “The objective of COVIPLASM trial (a nested trial in the CORIMUNO-19 COHORT) is to study the efficacy of convalescent plasma to treat SARS-COV2 infected patients.” NCT04345991 ↗ “This research proposes the passive administration of antibodies through the transfusion of convalescent plasma, in patients with severe COVID-19 disease.” NCT04542967 ↗ |
| Known as | anti-SARS-CoV-2 convalescent plasma | “This randomized, controlled, double-blinded phase 2 trial will assess the efficacy and safety of Anti- SARS-CoV-2 convalescent plasma as prophylaxis following exposure to...” NCT04323800 ↗1“anti-SARS-CoV-2 convalescent plasma (CP) in” NCT04358211 ↗ |
| Known as | anti-SARS-CoV-2 plasma | “Convalescent Plasma (anti-SARS-CoV-2 plasma)” NCT04359810 ↗ |
| Known as | C19-CP | “Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.” NCT04377568 ↗ |
| Known as | CCP | “COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the...” NCT04421404 ↗5“We have undertaken a randomized controlled trial to assess the efficacy and safety of COVID-19 convalescent plasma (CCP) in patients with SARS-CoV-2 infection.” PMID 33947446 ↗ May 2021 “Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results.” PMID 36351430 ↗ Oct 2022 “COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19.” PMID 34901997 ↗ Feb 2022 “COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19.” PMID 40937925 ↗ Sep 2025 “COVID-19 convalescent plasma (CCP) plus standard of care (SOC)” NCT04516811 ↗ |
| Known as | CCP1 | “High-titer Convalescent COVID-19 Plasma (CCP1)” NCT04524507 ↗ |
| Known as | CCP2 | “Standard-titer Convalescent COVID-19 plasma (CCP2)” NCT04524507 ↗ |
| Known as | Convalescent anti-SARS-CoV-2 plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04345289 ↗ |
| Known as | Convalescent COVID 19 Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04516954 ↗ |
| Known as | Convalescent COVID-19 donor plasma | “Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection.” NCT04362176 ↗ |
| Known as | ConvP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04589949 ↗ |
| Known as | COPLA | “Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation.” PMID 35387813 ↗ Apr 2022 |
| Known as | Coronavirus-90 | “The goal of this study is to evaluate the safety and effectiveness of Coronavirus-90 (COVID-19) convalescent plasma for the treatment of COVID-19.” NCT04432272 ↗ |
| Known as | COVID-19 convalescent plasma | “We have undertaken a randomized controlled trial to assess the efficacy and safety of COVID-19 convalescent plasma (CCP) in patients with SARS-CoV-2 infection.” PMID 33947446 ↗ May 202119“Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results.” PMID 36351430 ↗ Oct 2022 “COVID-19 convalescent plasma (CCP) was an early and widely adopted putative therapy for severe COVID-19.” PMID 36135380 ↗ Sep 2022 “COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19.” PMID 34901997 ↗ Feb 2022 “COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19.” PMID 40937925 ↗ Sep 2025 |
| Known as | COVID-19 Convalescent Plasma (CCP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04421404 ↗ |
| Known as | Fresh frozen plasma (FFP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02557672 ↗ |
| Known as | Human convalescent plasma | “Human convalescent plasma is an option for treatment of COVID-19” NCT04358211 ↗ |
| Known as | SARS-CoV-2 convalescent plasma | “SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be...” NCT04364737 ↗1“SARS-CoV-2 convalescent plasma (CP)” NCT04358211 ↗ |
| Known as | SARS-CoV-2 plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04411602 ↗ |
| Action | Inhibit | “may inhibit viral entry and replication” NCT04345991 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Fresh frozen plasma (FFP)” NCT02557672 ↗ |
| Route | Intravenous | “At the second drainage participants will receive 2 units, or about 500 ccs, of fresh frozen plasma intravenously, plus 1 bottle, or 50 ccs, of 25% albumin if more than 4 liters...” NCT04109144 ↗ |